BACKGROUND: Three-weekly high-dose cisplatin (100 mg/m2) is considered the standard systemic regimen given concurrently with postoperative or definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). However, due to unsatisfactory patient tolerance, various weekly low-dose schedules have been increasingly used in clinical practice. The aim of this meta-analysis was to compare the efficacy, safety, and compliance between these two approaches. MATERIALS AND METHODS: We systematically searched literature for prospective trials of patients with LA-SCCHN who received postoperative or definitive conventionally fractionated concurrent chemoradiation. Radiation doses were usually 60-66 gray (Gy) in the postoperative setting and 66-70 Gy in the definitive setting. Standard, three-weekly high-dose cisplatin (100 mg/m2, 3 doses) was compared with the weekly low-dose protocol (≤50 mg/m2, ≥6 doses). The primary endpoint was overall survival. Secondary outcomes comprised response rate, acute and late adverse events, and treatment compliance. RESULTS: Fifty-two studies with 4,209 patients were included in two separate meta-analyses according to the two clinical settings. There was no difference in treatment efficacy as measured by overall survival or response rate between the chemoradiation settings with low-dose weekly and high-dose three-weekly cisplatin regimens. In the definitive treatment setting, the weekly regimen was more compliant and significantly less toxic with respect to severe (grade 3-4) myelosuppression (leukopenia p = .0083; neutropenia p = .0024), severe nausea and/or vomiting (p < .0001), and severe nephrotoxicity (p = .0099). Although in the postoperative setting the two approaches were more equal in compliance and with clearly less differences in the cisplatin-induced toxicities, the weekly approach induced more grade 3-4 dysphagia (p = .0026) and weight loss (p < .0001). CONCLUSION: In LA-SCCHN, current evidence is insufficient to demonstrate a meaningful survival difference between the two dosing regimens. Prior to its adoption into routine clinical practice, the low-dose weekly approach needs to be prospectively compared with the standard three-weekly high-dose schedule. IMPLICATIONS FOR PRACTICE: Given concurrently with conventional radiotherapy in locally advanced head and neck cancer, high-dose three-weekly cisplatin has often been replaced with weekly low-dose infusions to increase compliance and decrease toxicity. The present meta-analysis suggests that both approaches might be equal in efficacy, both in the definitive and postoperative settings, but differ in toxicity. However, some toxicity data can be influenced by unbalanced representation, and the conclusions are not based on adequately sized prospective randomized studies. Therefore, low-dose weekly cisplatin should not be used outside clinical trials but first prospectively studied in adequately sized phase III trials versus the high-dose three-weekly approach.

Department of Head and Neck Medical Oncology National Cancer Center Hospital East Chiba Japan

Department of Hematology and Medical Oncology Taussig Cancer Institute Cleveland Clinic Cleveland Ohio USA

Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic

Department of Medical Oncology Antwerp University Hospital Edegem Belgium

Department of Medical Oncology Tata Memorial Hospital Mumbai Maharashtra India

Faculty of Medicine and Health Sciences University of Antwerp Antwerp Belgium

Head and Neck Medical Oncology Unit Fondazione IRCCS Istituto Nazionale dei Tumori Milan and University of Milan Milan Italy

Kobe University Hospital Cancer Center Hyogo Japan

Medical Oncology Centro Hospitalar do Porto Porto Portugal

School of Medicine Masaryk University Brno Czech Republic

Scientific Coordination and Biostatistics Antwerp University Hospital Edegem Belgium

Komentář v

Oncologist. 2017 Sep;22(9):1022-1023. doi: 10.1634/theoncologist.2017-0232. PubMed

Zobrazit více v PubMed

Adelstein DJ, Li Y, Adams GL et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92–98. PubMed

Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091–2098. PubMed

Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945–1952. PubMed

Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high‐risk squamous‐cell carcinoma of the head and neck. N Engl J Med 2004;350:1937–1944. PubMed

Forastiere AA, Zhang Q, Weber RS et al. Long‐term results of RTOG 91‐11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31:845–852. PubMed PMC

Hartmann JT, Kollmannsberger C, Kanz L et al. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999;83:866–869. PubMed

Schaake‐Koning C, van den Bogaert W, Dalesio O et al. Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups. Lung Cancer 1994;10(suppl 1):S263–S270. PubMed

Strojan P, Vermorken JB, Beitler JJ et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head Neck 2016;38(suppl 1):E2151–E2158. PubMed

Ang KK. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: Are we addressing burning subjects? J Clin Oncol 2004;22:4657–4659. PubMed

Ghi MG, Paccagnella A, Floriani I et al. Concomitant chemoradiation in locally advanced head and neck squamous cell carcinoma: A literature‐based meta‐analysis on the platinum concomitant chemotherapy. J Clin Oncol 2011;29:5534a.

Otty Z, Skinner MB, Dass J et al. Efficacy and tolerability of weekly low‐dose cisplatin concurrent with radiotherapy in head and neck cancer patients. Asia Pac J Clin Oncol 2011;7:287–292. PubMed

Spreafico A, Huang SH, Xu W et al. Impact of cisplatin dose intensity on human papillomavirus‐related and ‐unrelated locally advanced head and neck squamous cell carcinoma. Eur J Cancer 2016;67:174–182. PubMed

Vermorken JB, van der Vijgh WJ, Klein I et al. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 1986;39:136–144. PubMed

Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 2014;740:364–378. PubMed PMC

Johnson NP, Hoeschele JD, Rahn RO. Kinetic analysis of the in vitro binding of radioactive cis‐ and trans‐dichlorodiammineplatinum(II) to DNA. Chem Biol Interact 1980;30:151–169. PubMed

Traynor AM, Richards GM, Hartig GK et al. Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: The University of Wisconsin experience. Head Neck 2010;32:599–606. PubMed PMC

Medina JA, Rueda A, de Pasos AS et al. A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiother Oncol 2006;79:34–38. PubMed

Kurihara N, Kubota T, Hoshiya Y et al. Pharmacokinetics of cisdiamminedichloroplatinum (II) given as low‐dose and high‐dose infusions. J Surg Oncol 1996;62:135–138. PubMed

Newlin HE, Amdur RJ, Riggs CE et al. Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. Cancer 2010;116:4533–4540. PubMed

Beckmann GK, Hoppe F, Pfreundner L et al. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 2005;27:36–43. PubMed

Bartelink H, Kallman RF, Rapacchietta D et al. Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis‐diamminedichloroplatinum (II) and irradiation. Radiother Oncol 1986;6:61–74. PubMed

Marcu L, Bezak E, Olver I. Scheduling cisplatin and radiotherapy in the treatment of squamous cell carcinomas of the head and neck: A modelling approach. Phys Med Biol 2006;51:3625–3637. PubMed

Myint WK, Ng C, Raaphorst GP. Examining the non‐homologous repair process following cisplatin and radiation treatments. Int J Radiat Biol 2002;78:417–424. PubMed

Chan AT, Leung SF, Ngan RK et al. Overall survival after concurrent cisplatin‐radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536–539. PubMed

Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin‐based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144–1153. PubMed

Espeli V, Zucca E, Ghielmini M et al. Weekly and 3‐weekly cisplatin concurrent with intensity‐modulated radiotherapy in locally advanced head and neck squamous cell cancer. Oral Oncol 2012;48:266–271. PubMed

Wong SJ, Li L, Hess LM et al. Utilization and outcomes of low dose versus high dose cisplatin in head and neck cancer patients receiving concurrent radiation. J Clin Oncol 2015;33:6019a.

Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA statement. BMJ 2009;339:b2535. PubMed PMC

Arends LR, Hunink MG, Stijnen T. Meta‐analysis of summary survival curve data. Stat Med 2008;27:4381–4396. PubMed

Bachaud JM, David JM, Boussin G et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: Preliminary report of a randomized trial. Int J Radiat Oncol Biol Phys 1991;20:243–246. PubMed

Bachaud JM, Cohen‐Jonathan E, Alzieu C et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36:999–1004. PubMed

Rampino M, Ricardi U, Munoz F et al. Concomitant adjuvant chemoradiotherapy with weekly low‐dose cisplatin for high‐risk squamous cell carcinoma of the head and neck: A phase II prospective trial. Clin Oncol (R Coll Radiol) 2011;23:134–140. PubMed

Tsan DL, Lin CY, Kang CJ et al. The comparison between weekly and three‐weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high‐risk squamous cell carcinoma of the oral cavity. Radiat Oncol 2012;7:215. PubMed PMC

Al‐Sarraf M, Pajak TF, Byhardt RW et al. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88‐24. Int J Radiat Oncol Biol Phys 1997;37:777–782. PubMed

Cooper JS, Zhang Q, Pajak TF et al. Long‐term follow‐up of the RTOG 9501/intergroup phase III trial: Postoperative concurrent radiation therapy and chemotherapy in high‐risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012;84:1198–1205. PubMed PMC

Kiyota N, Tahara M, Okano S et al. Phase II feasibility trial of adjuvant chemoradiotherapy with 3‐weekly cisplatin for Japanese patients with post‐operative high‐risk squamous cell carcinoma of the head and neck. Jpn J Clin Oncol 2012;42:927–933. PubMed

Harrington K, Temam S, Mehanna H et al. Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib monotherapy in high‐risk patients with resected squamous cell carcinoma of the head and neck: A phase III, randomized, double‐blind, placebo‐controlled study. J Clin Oncol 2015;33:4202–4209. PubMed

Glaser MG, Leslie MD, O'Reilly SM et al. Weekly cisplatinum concomitant with radical radiotherapy in the treatment of advanced head and neck cancer. Clin Oncol (R Coll Radiol) 1993;5:286–289. PubMed

Asif R, Chandra K, Chopra V et al. Concurrent cisplatin and radiotherapy in advanced head and neck cancer. Indian J Otolaryngol Head Neck Surg 2003;55:94–96. PubMed PMC

Sarkar SK, Patra NB, Goswami J et al. Comparative study of efficacy and toxicities of cisplatin vs vinorelbine as radiosensitisers in locally advanced head and neck cancer. J Laryngol Otol 2008;122:188–192. PubMed

Jain RK, Kirar P, Gupta G et al. A comparative study of low dose weekly paclitaxel versus cisplatin with concurrent radiation in the treatment of locally advanced head and neck cancers. Indian J Cancer 2009;46:50–53. PubMed

Devleena, Majumdar A, Poddar S et al. Comparison of vinorelbine with cisplatin in concomitant chemoradiotherapy in head and neck carcinoma. Indian J Med Paediatr Oncol 2010;31:4–7. PubMed PMC

Essa HH, Azzam M. Concurrent chemoradiation in locally advanced head and neck cancers: A comparative study of weekly Paclitaxel versus Cisplatin‐based regimen. J Egypt Natl Canc Inst 2010;22:165–173. PubMed

Sharma A, Mohanti BK, Thakar A et al. Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: A phase II randomized trial. Ann Oncol 2010;21:2272–2277. PubMed

Kanotra SP, Kanotra S, Gupta A et al. Chemoradiation in advanced head and neck cancers: A comparison of two radiosensitizers, paclitaxel and cisplatin. Indian J Otolaryngol Head Neck Surg 2011;63:229–236. PubMed PMC

Quon H, Leong T, Haselow R et al. Phase III study of radiation therapy with or without cis‐platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: An intergroup trial of the Eastern Cooperative Oncology Group (E2382). Int J Radiat Oncol Biol Phys 2011;81:719–725. PubMed PMC

Abbas H, Bensadoun RJ. Trolamine emulsion for the prevention of radiation dermatitis in patients with squamous cell carcinoma of the head and neck. Support Care Cancer 2012;20:185–190. PubMed

Agrawal S, Awasthi R, Singh A et al. An exploratory study into the role of dynamic contrast‐enhanced (DCE) MRI metrics as predictors of response in head and neck cancers. Clin Radiol 2012;67:e1–e5. PubMed

Sharma A, Rath GK, Chaudhary SP et al. Lactobacillus brevis CD2 lozenges reduce radiation‐ and chemotherapy‐induced mucositis in patients with head and neck cancer: A randomized double‐blind placebo‐controlled study. Eur J Cancer 2012;48:875–881. PubMed

Majumder D, Choudhury K, Das P et al. Different fractionation schedules of radiotherapy in locally advanced head and neck malignancy: A prospective randomized study to compare the results of treatment and toxicities of different protocols. South Asian J Cancer 2013;2:31–35. PubMed PMC

Ghosh‐Laskar S, Kalyani N, Gupta T et al. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial. Head Neck 2016;38:202–207. PubMed

Al‐Sarraf M, Pajak TF, Marcial VA et al. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG Study. Cancer 1987;59:259–265. PubMed

Marcial VA, Pajak TF, Mohiuddin M et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long‐term results of the Radiation Therapy Oncology Group study 81‐17. Cancer 1990;66:1861–1868. PubMed

Fountzilas G, Skarlos D, Kosmidis P et al. Radiation therapy and concurrent cisplatin administration in locally advanced head and neck cancer. A Hellenic Co‐operative Oncology Group study. Acta Oncol 1994;33:825–830. PubMed

Pinnarò P, Cercato MC, Giannarelli D et al. A randomized phase II study comparing sequential versus simultaneous chemo‐radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck. Ann Oncol 1994;5:513–519. PubMed

Forastiere AA, Zhang Q, Weber RS et al. Long‐term results of RTOG 91‐11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31:845–852. PubMed PMC

Fountzilas G, Ciuleanu E, Dafni U et al. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: A Hellenic Cooperative Oncology Group Phase III Study. Med Oncol 2004;21:95–107. PubMed

de Castro G Jr, Snitcovsky IM, Gebrim EM et al. High‐dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non‐metastatic stage IV head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2007;264:1475–1482. PubMed

Zenda S, Onozawa Y, Tahara M et al. Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: Preliminary results. Jpn J Clin Oncol 2007;37:725–729. PubMed

Herchenhorn D, Dias FL, Ferreira CG et al. Impact of previous tracheotomy as a prognostic factor in patients with locally advanced squamous cell carcinoma of the larynx submitted to concomitant chemotherapy and radiation. ORL J Otorhinolaryngol Relat Spec 2008;70:381–388. PubMed

Prades JM, Lallemant B, Garrel R et al. Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma. Acta Otolaryngol 2010;130:150–155. PubMed

Rasch CR, Hauptmann M, Schornagel J et al. Intra‐arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial. Cancer 2010;116:2159–2165. PubMed

Rischin D, Peters LJ, O'Sullivan B et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans‐Tasman Radiation Oncology Group. J Clin Oncol 2010;28:2989–2995. PubMed

Gregoire V, Hamoir M, Chen C et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: A phase II, randomized, double‐blind, placebo‐controlled study. Radiother Oncol 2011;100:62–69. PubMed

Le QT, Kim HE, Schneider CJ et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: A randomized, placebo‐controlled study. J Clin Oncol 2011;29:2808–2814. PubMed

Gautam AP, Fernandes DJ, Vidyasagar MS et al. Low level laser therapy for concurrent chemoradiotherapy induced oral mucositis in head and neck cancer patients ‐ A triple blinded randomized controlled trial. Radiother Oncol 2012;104:349–354. PubMed

Antunes HS, Herchenhorn D, Small IA et al. Phase III trial of low‐level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation. Radiother Oncol 2013;109:297–302. PubMed

Harrington K, Berrier A, Robinson M et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus‐negative disease. Eur J Cancer 2013;49:1609–1618. PubMed

Martins RG, Parvathaneni U, Bauman JE et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial. J Clin Oncol 2013;31:1415–1421. PubMed

Rishi A, Ghoshal S, Verma R et al. Comparison of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced oropharyngeal cancers: A phase III randomised trial. Radiother Oncol 2013;107:317–324. PubMed

Hitt R, Grau JJ, López‐Pousa A et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 2014;25:216–225. PubMed

Nguyen‐Tan PF, Zhang Q, Ang KK et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: Long‐term report of efficacy and toxicity. J Clin Oncol 2014;32:3858–3866. PubMed PMC

Rodriguez CP, Adelstein DJ, Rybicki LA et al. Randomized phase III study of 2 cisplatin‐based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: Impact of changing disease epidemiology on contemporary trial design. Head Neck 2015;37:1583–1589. PubMed

Diaz‐Sanchez RM, Pachón‐Ibáñez J, Marín‐Conde F et al. Double‐blind, randomized pilot study of bioadhesive chlorhexidine gel in the prevention and treatment of mucositis induced by chemoradiotherapy of head and neck cancer. Med Oral Patol Oral Cir Bucal 2015;20:e378–e385. PubMed PMC

Mesía R, Henke M, Fortin A et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous‐cell carcinoma of the head and neck (CONCERT‐1): A randomised, controlled, open‐label phase 2 trial. Lancet Oncol 2015;16:208–220. PubMed

Takácsi‐Nagy Z, Hitre E, Remenár É et al. Docetaxel, cisplatin and 5‐fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III‐IV unresectable head and neck cancer: Results of a randomized phase II study. Strahlenther Onkol 2015;191:635–641. PubMed

Reeves BC, Deeks JJ, Higgins JPT et al. Chapter 13: Including non‐randomised studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from http://www.handbook.cochrane.org. Accessed on April 13, 2017.

Geeta SN, Padmanabhan TK, Samuel J et al. Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers. J Cancer Res Ther 2006;2:100–104. PubMed

Ho KF, Swindell R, Brammer CV. Dose intensity comparison between weekly and 3‐weekly cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: A retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol 2008;47:1513–1518. PubMed

Uygun K, Bilici A, Karagol H et al. The comparison of weekly and three‐weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non‐metastatic squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2009;64:601–605. PubMed

Kose F, Besen A, Sumbul T et al. Weekly cisplatin versus standard three‐weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: The Baskent University experience. Asian Pac J Cancer Prev 2011;12:1185–1188. PubMed

Geiger JL, Lazim AF, Walsh FJ et al. Adjuvant chemoradiation therapy with high‐dose versus weekly cisplatin for resected, locally‐advanced HPV/p16‐positive and negative head and neck squamous cell carcinoma. Oral Oncol 2014;50:311–318. PubMed

Kunieda F, Kiyota N, Tahara M et al. Randomized phase II/III trial of post‐operative chemoradiotherapy comparing 3‐weekly cisplatin with weekly cisplatin in high‐risk patients with squamous cell carcinoma of head and neck: Japan Clinical Oncology Group Study (JCOG1008). Jpn J Clin Oncol 2014;44:770–774. PubMed